Pain Management Drugs Market By Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics) , By Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, Fibromyalgia, Muscle Sprain/Strain, Bone Fracture, Acute Appendicitis, Others) By Pain Type (Chronic Pain, Acute Pain) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Pain Management Drugs Market
The pain management drugs market was valued at $72.6 billion in 2023 and is projected t%li%reach $109.6 billion by 2033, growing at a CAGR of 4.2% from 2024 t%li%2033.
A pain management drug is medication prescribed for the alleviation of pain ranging from moderate discomfort t%li%severe distress. The formulation of pain management drugs comprises of different drug class, including opioids, antidepressants or acetaminophen. These medications target diverse pain types, including musculoskeletal, neuropathic, and inflammatory pain. The mechanisms pertaining t%li%the functioning of pain management drug are diverse such as lowering of inflammation, inhibition of pain signals in the nervous system, or alteration of brain chemistry t%li%modulate the perception of pain.
Increase in the prevalence of lifestyle and chronic diseases such as stroke, heart disease, type II diabetes, and cancer is driving the pain management drugs market. In addition, advancements in drug formulations and delivery methods such as extended-release formulations with reduced dosing frequency are boosting the demand for the drugs as they enhance patient compliance & treatment outcomes. In recent times, explorations in nanotherapeutics are trending in the market as nanoparticles are anticipated t%li%possess the capability of precisely identifying the target and offering long-term efficacy in significantly low dosage.
However, the severe side-effects of pain management drugs; including cardiovascular events, gastrointestinal bleeding, sedation, renal impairment, and respiratory depression; limit their consumption, hence presenting challenges for market expansion. T%li%eliminate the hazards of conventional drugs, natural alternatives are being explored as they have potentially minimal t%li%n%li%side-effects. For instance, Kratom, a herbal substance obtained from the Mitragyna speciosa tree, is being utilized as an alternative t%li%opioid drugs. Kratom medications have proved t%li%be highly effective in providing relief from chronic pain conditions such as fibromyalgia & arthritis and neuropathic pain.
Segment Review
The pain management drugs market is segmented int%li%drug class, indication, pain type, and region. On the basis of drug class, the market is divided int%li%NSAIDs, anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. As per indication, it is classified int%li%arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, muscle sprain/strain, bone fracture, acute appendicitis, and others. By pain type, it is bifurcated int%li%chronic pain and acute pain. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of drug class, the opioids segment is expected t%li%dominate the market during the forecast period.
As per indication, the postoperative pain segment is predicted t%li%be the highest shareholder by 2033.
By pain type, the chronic pain segment is anticipated t%li%lead the market during the forecast period.
Region wise, North America is projected t%li%be the highest revenue generator by 2033.
Competition Analysis
The major players operating in the global pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, End%li%Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc., Viatris Inc., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships t%li%strengthen their foothold in the market.
Additional benefits you will get with this purchase are:
By Drug Class
The pain management drugs market was valued at $72.6 billion in 2023 and is projected t%li%reach $109.6 billion by 2033, growing at a CAGR of 4.2% from 2024 t%li%2033.
A pain management drug is medication prescribed for the alleviation of pain ranging from moderate discomfort t%li%severe distress. The formulation of pain management drugs comprises of different drug class, including opioids, antidepressants or acetaminophen. These medications target diverse pain types, including musculoskeletal, neuropathic, and inflammatory pain. The mechanisms pertaining t%li%the functioning of pain management drug are diverse such as lowering of inflammation, inhibition of pain signals in the nervous system, or alteration of brain chemistry t%li%modulate the perception of pain.
Increase in the prevalence of lifestyle and chronic diseases such as stroke, heart disease, type II diabetes, and cancer is driving the pain management drugs market. In addition, advancements in drug formulations and delivery methods such as extended-release formulations with reduced dosing frequency are boosting the demand for the drugs as they enhance patient compliance & treatment outcomes. In recent times, explorations in nanotherapeutics are trending in the market as nanoparticles are anticipated t%li%possess the capability of precisely identifying the target and offering long-term efficacy in significantly low dosage.
However, the severe side-effects of pain management drugs; including cardiovascular events, gastrointestinal bleeding, sedation, renal impairment, and respiratory depression; limit their consumption, hence presenting challenges for market expansion. T%li%eliminate the hazards of conventional drugs, natural alternatives are being explored as they have potentially minimal t%li%n%li%side-effects. For instance, Kratom, a herbal substance obtained from the Mitragyna speciosa tree, is being utilized as an alternative t%li%opioid drugs. Kratom medications have proved t%li%be highly effective in providing relief from chronic pain conditions such as fibromyalgia & arthritis and neuropathic pain.
Segment Review
The pain management drugs market is segmented int%li%drug class, indication, pain type, and region. On the basis of drug class, the market is divided int%li%NSAIDs, anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. As per indication, it is classified int%li%arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, muscle sprain/strain, bone fracture, acute appendicitis, and others. By pain type, it is bifurcated int%li%chronic pain and acute pain. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of drug class, the opioids segment is expected t%li%dominate the market during the forecast period.
As per indication, the postoperative pain segment is predicted t%li%be the highest shareholder by 2033.
By pain type, the chronic pain segment is anticipated t%li%lead the market during the forecast period.
Region wise, North America is projected t%li%be the highest revenue generator by 2033.
Competition Analysis
The major players operating in the global pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, End%li%Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc., Viatris Inc., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships t%li%strengthen their foothold in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting t%li%16 analyst hours t%li%solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent t%li%3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
- Regulatory Guidelines
- Additional company profiles with specific t%li%client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
By Drug Class
- NSAIDs
- Anesthetics
- Anticonvulsants
- Anti-migraine Agents
- Antidepressants
- Opioids
- Nonnarcotic Analgesics
- Arthritic Pain
- Neuropathic Pain
- Cancer Pain
- Chronic Back Pain
- Postoperative Pain
- Migraine
- Fibromyalgia
- Muscle Sprain/Strain
- Bone Fracture
- Acute Appendicitis
- Others
- Chronic Pain
- Acute Pain
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Novartis AG
- Eli Lilly & Company
- Abbott Laboratories
- End%li%Health Solutions, Inc.
- Purdue Pharma L.P.
- Pfizer, Inc.
- Viatris Inc.
- Merck & Co. Inc.
- Johnson & Johnson
- GlaxoSmithKline Plc
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: HUMAN INSULIN MARKET, BY PRODUCT TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Product Type
4.2. Pens
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Syringes
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Others
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: HUMAN INSULIN MARKET, BY INDICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Indication
5.2. Type 1 Diabetes
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Type 2 Diabetes
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Gestational Diabetes
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: HUMAN INSULIN MARKET, BY TYPE OF INSULIN
6.1. Market Overview
6.1.1 Market Size and Forecast, By Type of Insulin
6.2. Rapid-acting Insulin
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Short-acting Insulin
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Intermediate-acting Insulin
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
6.5. Others
6.5.1. Key Market Trends, Growth Factors and Opportunities
6.5.2. Market Size and Forecast, By Region
6.5.3. Market Share Analysis, By Country
CHAPTER 7: HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL
7.1. Market Overview
7.1.1 Market Size and Forecast, By Distribution Channel
7.2. Hospital Pharmacies
7.2.1. Key Market Trends, Growth Factors and Opportunities
7.2.2. Market Size and Forecast, By Region
7.2.3. Market Share Analysis, By Country
7.3. Drug Stores And Retail Pharmacies
7.3.1. Key Market Trends, Growth Factors and Opportunities
7.3.2. Market Size and Forecast, By Region
7.3.3. Market Share Analysis, By Country
7.4. Online Providers
7.4.1. Key Market Trends, Growth Factors and Opportunities
7.4.2. Market Size and Forecast, By Region
7.4.3. Market Share Analysis, By Country
CHAPTER 8: HUMAN INSULIN MARKET, BY REGION
8.1. Market Overview
8.1.1 Market Size and Forecast, By Region
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. Market Size and Forecast, By Product Type
8.2.3. Market Size and Forecast, By Indication
8.2.4. Market Size and Forecast, By Type of Insulin
8.2.5. Market Size and Forecast, By Distribution Channel
8.2.6. Market Size and Forecast, By Country
8.2.7. U.S. Human Insulin Market
8.2.7.1. Market Size and Forecast, By Product Type
8.2.7.2. Market Size and Forecast, By Indication
8.2.7.3. Market Size and Forecast, By Type of Insulin
8.2.7.4. Market Size and Forecast, By Distribution Channel
8.2.8. Canada Human Insulin Market
8.2.8.1. Market Size and Forecast, By Product Type
8.2.8.2. Market Size and Forecast, By Indication
8.2.8.3. Market Size and Forecast, By Type of Insulin
8.2.8.4. Market Size and Forecast, By Distribution Channel
8.2.9. Mexico Human Insulin Market
8.2.9.1. Market Size and Forecast, By Product Type
8.2.9.2. Market Size and Forecast, By Indication
8.2.9.3. Market Size and Forecast, By Type of Insulin
8.2.9.4. Market Size and Forecast, By Distribution Channel
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Market Size and Forecast, By Product Type
8.3.3. Market Size and Forecast, By Indication
8.3.4. Market Size and Forecast, By Type of Insulin
8.3.5. Market Size and Forecast, By Distribution Channel
8.3.6. Market Size and Forecast, By Country
8.3.7. Germany Human Insulin Market
8.3.7.1. Market Size and Forecast, By Product Type
8.3.7.2. Market Size and Forecast, By Indication
8.3.7.3. Market Size and Forecast, By Type of Insulin
8.3.7.4. Market Size and Forecast, By Distribution Channel
8.3.8. France Human Insulin Market
8.3.8.1. Market Size and Forecast, By Product Type
8.3.8.2. Market Size and Forecast, By Indication
8.3.8.3. Market Size and Forecast, By Type of Insulin
8.3.8.4. Market Size and Forecast, By Distribution Channel
8.3.9. UK Human Insulin Market
8.3.9.1. Market Size and Forecast, By Product Type
8.3.9.2. Market Size and Forecast, By Indication
8.3.9.3. Market Size and Forecast, By Type of Insulin
8.3.9.4. Market Size and Forecast, By Distribution Channel
8.3.10. Italy Human Insulin Market
8.3.10.1. Market Size and Forecast, By Product Type
8.3.10.2. Market Size and Forecast, By Indication
8.3.10.3. Market Size and Forecast, By Type of Insulin
8.3.10.4. Market Size and Forecast, By Distribution Channel
8.3.11. Spain Human Insulin Market
8.3.11.1. Market Size and Forecast, By Product Type
8.3.11.2. Market Size and Forecast, By Indication
8.3.11.3. Market Size and Forecast, By Type of Insulin
8.3.11.4. Market Size and Forecast, By Distribution Channel
8.3.12. Rest of Europe Human Insulin Market
8.3.12.1. Market Size and Forecast, By Product Type
8.3.12.2. Market Size and Forecast, By Indication
8.3.12.3. Market Size and Forecast, By Type of Insulin
8.3.12.4. Market Size and Forecast, By Distribution Channel
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Market Size and Forecast, By Product Type
8.4.3. Market Size and Forecast, By Indication
8.4.4. Market Size and Forecast, By Type of Insulin
8.4.5. Market Size and Forecast, By Distribution Channel
8.4.6. Market Size and Forecast, By Country
8.4.7. Japan Human Insulin Market
8.4.7.1. Market Size and Forecast, By Product Type
8.4.7.2. Market Size and Forecast, By Indication
8.4.7.3. Market Size and Forecast, By Type of Insulin
8.4.7.4. Market Size and Forecast, By Distribution Channel
8.4.8. China Human Insulin Market
8.4.8.1. Market Size and Forecast, By Product Type
8.4.8.2. Market Size and Forecast, By Indication
8.4.8.3. Market Size and Forecast, By Type of Insulin
8.4.8.4. Market Size and Forecast, By Distribution Channel
8.4.9. India Human Insulin Market
8.4.9.1. Market Size and Forecast, By Product Type
8.4.9.2. Market Size and Forecast, By Indication
8.4.9.3. Market Size and Forecast, By Type of Insulin
8.4.9.4. Market Size and Forecast, By Distribution Channel
8.4.10. Australia Human Insulin Market
8.4.10.1. Market Size and Forecast, By Product Type
8.4.10.2. Market Size and Forecast, By Indication
8.4.10.3. Market Size and Forecast, By Type of Insulin
8.4.10.4. Market Size and Forecast, By Distribution Channel
8.4.11. South Korea Human Insulin Market
8.4.11.1. Market Size and Forecast, By Product Type
8.4.11.2. Market Size and Forecast, By Indication
8.4.11.3. Market Size and Forecast, By Type of Insulin
8.4.11.4. Market Size and Forecast, By Distribution Channel
8.4.12. Rest of Asia-Pacific Human Insulin Market
8.4.12.1. Market Size and Forecast, By Product Type
8.4.12.2. Market Size and Forecast, By Indication
8.4.12.3. Market Size and Forecast, By Type of Insulin
8.4.12.4. Market Size and Forecast, By Distribution Channel
8.5. LAMEA
8.5.1. Key Market Trends and Opportunities
8.5.2. Market Size and Forecast, By Product Type
8.5.3. Market Size and Forecast, By Indication
8.5.4. Market Size and Forecast, By Type of Insulin
8.5.5. Market Size and Forecast, By Distribution Channel
8.5.6. Market Size and Forecast, By Country
8.5.7. Brazil Human Insulin Market
8.5.7.1. Market Size and Forecast, By Product Type
8.5.7.2. Market Size and Forecast, By Indication
8.5.7.3. Market Size and Forecast, By Type of Insulin
8.5.7.4. Market Size and Forecast, By Distribution Channel
8.5.8. Saudi Arabia Human Insulin Market
8.5.8.1. Market Size and Forecast, By Product Type
8.5.8.2. Market Size and Forecast, By Indication
8.5.8.3. Market Size and Forecast, By Type of Insulin
8.5.8.4. Market Size and Forecast, By Distribution Channel
8.5.9. South Africa Human Insulin Market
8.5.9.1. Market Size and Forecast, By Product Type
8.5.9.2. Market Size and Forecast, By Indication
8.5.9.3. Market Size and Forecast, By Type of Insulin
8.5.9.4. Market Size and Forecast, By Distribution Channel
8.5.10. Rest of LAMEA Human Insulin Market
8.5.10.1. Market Size and Forecast, By Product Type
8.5.10.2. Market Size and Forecast, By Indication
8.5.10.3. Market Size and Forecast, By Type of Insulin
8.5.10.4. Market Size and Forecast, By Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top Winning Strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top Player Positioning, 2023
CHAPTER 10: COMPANY PROFILES
10.1. Eli Lilly And Company
10.1.1. Company Overview
10.1.2. Key Executives
10.1.3. Company Snapshot
10.1.4. Operating Business Segments
10.1.5. Product Portfolio
10.1.6. Business Performance
10.1.7. Key Strategic Moves and Developments
10.2. Sanofi
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Company Snapshot
10.2.4. Operating Business Segments
10.2.5. Product Portfolio
10.2.6. Business Performance
10.2.7. Key Strategic Moves and Developments
10.3. Novo Nordisk A/S
10.3.1. Company Overview
10.3.2. Key Executives
10.3.3. Company Snapshot
10.3.4. Operating Business Segments
10.3.5. Product Portfolio
10.3.6. Business Performance
10.3.7. Key Strategic Moves and Developments
10.4. Pfizer
10.4.1. Company Overview
10.4.2. Key Executives
10.4.3. Company Snapshot
10.4.4. Operating Business Segments
10.4.5. Product Portfolio
10.4.6. Business Performance
10.4.7. Key Strategic Moves and Developments
10.5. Biocon
10.5.1. Company Overview
10.5.2. Key Executives
10.5.3. Company Snapshot
10.5.4. Operating Business Segments
10.5.5. Product Portfolio
10.5.6. Business Performance
10.5.7. Key Strategic Moves and Developments
10.6. Wockhardt
10.6.1. Company Overview
10.6.2. Key Executives
10.6.3. Company Snapshot
10.6.4. Operating Business Segments
10.6.5. Product Portfolio
10.6.6. Business Performance
10.6.7. Key Strategic Moves and Developments
10.7. MannKind Corporation
10.7.1. Company Overview
10.7.2. Key Executives
10.7.3. Company Snapshot
10.7.4. Operating Business Segments
10.7.5. Product Portfolio
10.7.6. Business Performance
10.7.7. Key Strategic Moves and Developments
10.8. Tonghua Dongbao Pharmaceutical Co., Ltd.
10.8.1. Company Overview
10.8.2. Key Executives
10.8.3. Company Snapshot
10.8.4. Operating Business Segments
10.8.5. Product Portfolio
10.8.6. Business Performance
10.8.7. Key Strategic Moves and Developments
10.9. Medtronic
10.9.1. Company Overview
10.9.2. Key Executives
10.9.3. Company Snapshot
10.9.4. Operating Business Segments
10.9.5. Product Portfolio
10.9.6. Business Performance
10.9.7. Key Strategic Moves and Developments
10.10. Lupin
10.10.1. Company Overview
10.10.2. Key Executives
10.10.3. Company Snapshot
10.10.4. Operating Business Segments
10.10.5. Product Portfolio
10.10.6. Business Performance
10.10.7. Key Strategic Moves and Developments
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: HUMAN INSULIN MARKET, BY PRODUCT TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Product Type
4.2. Pens
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Syringes
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Others
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: HUMAN INSULIN MARKET, BY INDICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Indication
5.2. Type 1 Diabetes
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Type 2 Diabetes
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Gestational Diabetes
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: HUMAN INSULIN MARKET, BY TYPE OF INSULIN
6.1. Market Overview
6.1.1 Market Size and Forecast, By Type of Insulin
6.2. Rapid-acting Insulin
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Short-acting Insulin
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Intermediate-acting Insulin
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
6.5. Others
6.5.1. Key Market Trends, Growth Factors and Opportunities
6.5.2. Market Size and Forecast, By Region
6.5.3. Market Share Analysis, By Country
CHAPTER 7: HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL
7.1. Market Overview
7.1.1 Market Size and Forecast, By Distribution Channel
7.2. Hospital Pharmacies
7.2.1. Key Market Trends, Growth Factors and Opportunities
7.2.2. Market Size and Forecast, By Region
7.2.3. Market Share Analysis, By Country
7.3. Drug Stores And Retail Pharmacies
7.3.1. Key Market Trends, Growth Factors and Opportunities
7.3.2. Market Size and Forecast, By Region
7.3.3. Market Share Analysis, By Country
7.4. Online Providers
7.4.1. Key Market Trends, Growth Factors and Opportunities
7.4.2. Market Size and Forecast, By Region
7.4.3. Market Share Analysis, By Country
CHAPTER 8: HUMAN INSULIN MARKET, BY REGION
8.1. Market Overview
8.1.1 Market Size and Forecast, By Region
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. Market Size and Forecast, By Product Type
8.2.3. Market Size and Forecast, By Indication
8.2.4. Market Size and Forecast, By Type of Insulin
8.2.5. Market Size and Forecast, By Distribution Channel
8.2.6. Market Size and Forecast, By Country
8.2.7. U.S. Human Insulin Market
8.2.7.1. Market Size and Forecast, By Product Type
8.2.7.2. Market Size and Forecast, By Indication
8.2.7.3. Market Size and Forecast, By Type of Insulin
8.2.7.4. Market Size and Forecast, By Distribution Channel
8.2.8. Canada Human Insulin Market
8.2.8.1. Market Size and Forecast, By Product Type
8.2.8.2. Market Size and Forecast, By Indication
8.2.8.3. Market Size and Forecast, By Type of Insulin
8.2.8.4. Market Size and Forecast, By Distribution Channel
8.2.9. Mexico Human Insulin Market
8.2.9.1. Market Size and Forecast, By Product Type
8.2.9.2. Market Size and Forecast, By Indication
8.2.9.3. Market Size and Forecast, By Type of Insulin
8.2.9.4. Market Size and Forecast, By Distribution Channel
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Market Size and Forecast, By Product Type
8.3.3. Market Size and Forecast, By Indication
8.3.4. Market Size and Forecast, By Type of Insulin
8.3.5. Market Size and Forecast, By Distribution Channel
8.3.6. Market Size and Forecast, By Country
8.3.7. Germany Human Insulin Market
8.3.7.1. Market Size and Forecast, By Product Type
8.3.7.2. Market Size and Forecast, By Indication
8.3.7.3. Market Size and Forecast, By Type of Insulin
8.3.7.4. Market Size and Forecast, By Distribution Channel
8.3.8. France Human Insulin Market
8.3.8.1. Market Size and Forecast, By Product Type
8.3.8.2. Market Size and Forecast, By Indication
8.3.8.3. Market Size and Forecast, By Type of Insulin
8.3.8.4. Market Size and Forecast, By Distribution Channel
8.3.9. UK Human Insulin Market
8.3.9.1. Market Size and Forecast, By Product Type
8.3.9.2. Market Size and Forecast, By Indication
8.3.9.3. Market Size and Forecast, By Type of Insulin
8.3.9.4. Market Size and Forecast, By Distribution Channel
8.3.10. Italy Human Insulin Market
8.3.10.1. Market Size and Forecast, By Product Type
8.3.10.2. Market Size and Forecast, By Indication
8.3.10.3. Market Size and Forecast, By Type of Insulin
8.3.10.4. Market Size and Forecast, By Distribution Channel
8.3.11. Spain Human Insulin Market
8.3.11.1. Market Size and Forecast, By Product Type
8.3.11.2. Market Size and Forecast, By Indication
8.3.11.3. Market Size and Forecast, By Type of Insulin
8.3.11.4. Market Size and Forecast, By Distribution Channel
8.3.12. Rest of Europe Human Insulin Market
8.3.12.1. Market Size and Forecast, By Product Type
8.3.12.2. Market Size and Forecast, By Indication
8.3.12.3. Market Size and Forecast, By Type of Insulin
8.3.12.4. Market Size and Forecast, By Distribution Channel
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Market Size and Forecast, By Product Type
8.4.3. Market Size and Forecast, By Indication
8.4.4. Market Size and Forecast, By Type of Insulin
8.4.5. Market Size and Forecast, By Distribution Channel
8.4.6. Market Size and Forecast, By Country
8.4.7. Japan Human Insulin Market
8.4.7.1. Market Size and Forecast, By Product Type
8.4.7.2. Market Size and Forecast, By Indication
8.4.7.3. Market Size and Forecast, By Type of Insulin
8.4.7.4. Market Size and Forecast, By Distribution Channel
8.4.8. China Human Insulin Market
8.4.8.1. Market Size and Forecast, By Product Type
8.4.8.2. Market Size and Forecast, By Indication
8.4.8.3. Market Size and Forecast, By Type of Insulin
8.4.8.4. Market Size and Forecast, By Distribution Channel
8.4.9. India Human Insulin Market
8.4.9.1. Market Size and Forecast, By Product Type
8.4.9.2. Market Size and Forecast, By Indication
8.4.9.3. Market Size and Forecast, By Type of Insulin
8.4.9.4. Market Size and Forecast, By Distribution Channel
8.4.10. Australia Human Insulin Market
8.4.10.1. Market Size and Forecast, By Product Type
8.4.10.2. Market Size and Forecast, By Indication
8.4.10.3. Market Size and Forecast, By Type of Insulin
8.4.10.4. Market Size and Forecast, By Distribution Channel
8.4.11. South Korea Human Insulin Market
8.4.11.1. Market Size and Forecast, By Product Type
8.4.11.2. Market Size and Forecast, By Indication
8.4.11.3. Market Size and Forecast, By Type of Insulin
8.4.11.4. Market Size and Forecast, By Distribution Channel
8.4.12. Rest of Asia-Pacific Human Insulin Market
8.4.12.1. Market Size and Forecast, By Product Type
8.4.12.2. Market Size and Forecast, By Indication
8.4.12.3. Market Size and Forecast, By Type of Insulin
8.4.12.4. Market Size and Forecast, By Distribution Channel
8.5. LAMEA
8.5.1. Key Market Trends and Opportunities
8.5.2. Market Size and Forecast, By Product Type
8.5.3. Market Size and Forecast, By Indication
8.5.4. Market Size and Forecast, By Type of Insulin
8.5.5. Market Size and Forecast, By Distribution Channel
8.5.6. Market Size and Forecast, By Country
8.5.7. Brazil Human Insulin Market
8.5.7.1. Market Size and Forecast, By Product Type
8.5.7.2. Market Size and Forecast, By Indication
8.5.7.3. Market Size and Forecast, By Type of Insulin
8.5.7.4. Market Size and Forecast, By Distribution Channel
8.5.8. Saudi Arabia Human Insulin Market
8.5.8.1. Market Size and Forecast, By Product Type
8.5.8.2. Market Size and Forecast, By Indication
8.5.8.3. Market Size and Forecast, By Type of Insulin
8.5.8.4. Market Size and Forecast, By Distribution Channel
8.5.9. South Africa Human Insulin Market
8.5.9.1. Market Size and Forecast, By Product Type
8.5.9.2. Market Size and Forecast, By Indication
8.5.9.3. Market Size and Forecast, By Type of Insulin
8.5.9.4. Market Size and Forecast, By Distribution Channel
8.5.10. Rest of LAMEA Human Insulin Market
8.5.10.1. Market Size and Forecast, By Product Type
8.5.10.2. Market Size and Forecast, By Indication
8.5.10.3. Market Size and Forecast, By Type of Insulin
8.5.10.4. Market Size and Forecast, By Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top Winning Strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top Player Positioning, 2023
CHAPTER 10: COMPANY PROFILES
10.1. Eli Lilly And Company
10.1.1. Company Overview
10.1.2. Key Executives
10.1.3. Company Snapshot
10.1.4. Operating Business Segments
10.1.5. Product Portfolio
10.1.6. Business Performance
10.1.7. Key Strategic Moves and Developments
10.2. Sanofi
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Company Snapshot
10.2.4. Operating Business Segments
10.2.5. Product Portfolio
10.2.6. Business Performance
10.2.7. Key Strategic Moves and Developments
10.3. Novo Nordisk A/S
10.3.1. Company Overview
10.3.2. Key Executives
10.3.3. Company Snapshot
10.3.4. Operating Business Segments
10.3.5. Product Portfolio
10.3.6. Business Performance
10.3.7. Key Strategic Moves and Developments
10.4. Pfizer
10.4.1. Company Overview
10.4.2. Key Executives
10.4.3. Company Snapshot
10.4.4. Operating Business Segments
10.4.5. Product Portfolio
10.4.6. Business Performance
10.4.7. Key Strategic Moves and Developments
10.5. Biocon
10.5.1. Company Overview
10.5.2. Key Executives
10.5.3. Company Snapshot
10.5.4. Operating Business Segments
10.5.5. Product Portfolio
10.5.6. Business Performance
10.5.7. Key Strategic Moves and Developments
10.6. Wockhardt
10.6.1. Company Overview
10.6.2. Key Executives
10.6.3. Company Snapshot
10.6.4. Operating Business Segments
10.6.5. Product Portfolio
10.6.6. Business Performance
10.6.7. Key Strategic Moves and Developments
10.7. MannKind Corporation
10.7.1. Company Overview
10.7.2. Key Executives
10.7.3. Company Snapshot
10.7.4. Operating Business Segments
10.7.5. Product Portfolio
10.7.6. Business Performance
10.7.7. Key Strategic Moves and Developments
10.8. Tonghua Dongbao Pharmaceutical Co., Ltd.
10.8.1. Company Overview
10.8.2. Key Executives
10.8.3. Company Snapshot
10.8.4. Operating Business Segments
10.8.5. Product Portfolio
10.8.6. Business Performance
10.8.7. Key Strategic Moves and Developments
10.9. Medtronic
10.9.1. Company Overview
10.9.2. Key Executives
10.9.3. Company Snapshot
10.9.4. Operating Business Segments
10.9.5. Product Portfolio
10.9.6. Business Performance
10.9.7. Key Strategic Moves and Developments
10.10. Lupin
10.10.1. Company Overview
10.10.2. Key Executives
10.10.3. Company Snapshot
10.10.4. Operating Business Segments
10.10.5. Product Portfolio
10.10.6. Business Performance
10.10.7. Key Strategic Moves and Developments
